Anti-Mesothelin CAR-T Cells
The Anti-mesothelin CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-Mesothelin CAR Lentivirus (Mesothelin ScFv-CD8-4-1BB-CD3ζ; BPS Bioscience #78703). These ready-to use CAR-T cells express an anti-Mesothelin CAR consisting of the scFv (Single chain fragment variable) of anti-Mesothelin (clone P4) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1).
These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.
Figure 1: Construct diagram showing components of the anti-Mesothelin CAR expressed in anti-Mesothelin CAR-T cells.
Name | Ordering Information |
Human Interleukin-2 | BPS Bioscience #90184 |
Human CD3/CD28/CD2 T Cell Activator | Stemcell Technologies #10970 |
Biotinylated Human Mesothelin | BPS Bioscience #100291 |
PE-Streptavidin | Biolegend #405203 |
Mesothelin- CHO Recombinant Cell Line | BPS Bioscience #78132 |
IFN-g (Human) Colorimetric ELISA Detection Kit | BPS Bioscience #79777 |
Recommended anti-Mesothelin CAR-T Cell Medium: TCellM™ (BPS Bioscience #78753) supplemented with 10 ng/ml Interleukin-2 (BPS Bioscience #90184).
The cells have been screened to confirm the absence of Mycoplasma species.
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI) linked cell-surface protein that is produced as a ~70 kDa precursor protein and cleaved by Furin protease to generate the ~40 kDa mature form. MSLN is frequently overexpressed in mesothelioma, ovarian, pancreatic, and non-small cell lung cancers, while its expression in normal tissues is restricted to the mesothelial lining. MSLN is a tumor-associated antigen and has been an attractive target for targeted immunotherapy approaches, including drug-conjugated antibodies and chimeric antigen receptor T cells (CAR-T Cells).